Review
doi: 10.1097/01.inf.0000259996.95965.ef.
Use of meningococcal vaccines in the United States
Affiliations
- PMID: 17468644
- DOI: 10.1097/01.inf.0000259996.95965.ef
Item in Clipboard
Review
Use of meningococcal vaccines in the United States
Pediatr Infect Dis J.
2007 May.
Abstract
In January 2005, Food and Drug Administration licensed a new tetravalent (serogroups A, C, Y, W-135) meningococcal conjugate vaccine ([MCV4] Menactra) for use in persons 11-55 years of age. In February 2005, CDC's Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination of adolescents and college freshmen living in dormitories with MCV4. The manufacturer started shipments of MCV4 in March 2005. MCV4 should become a key addition to existing meningococcal disease prevention measures.
Similar articles
-
Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005.MMWR Morb Mortal Wkly Rep. 2005 Oct 14;54(40):1023-5. MMWR Morb Mortal Wkly Rep. 2005. PMID: 16224452
-
Menactra: a meningococcal conjugate vaccine.Med Lett Drugs Ther. 2005 Apr 11;47(1206):29-31. Med Lett Drugs Ther. 2005. PMID: 15821633
-
Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients.Pediatrics. 2005 Aug;116(2):496-505. doi: 10.1542/peds.2005-1314. Epub 2005 Jul 1. Pediatrics. 2005. PMID: 15995007
-
Prevention of meningococcal disease.Am Fam Physician. 2005 Nov 15;72(10):2049-56. Am Fam Physician. 2005. PMID: 16342836 Review.
-
Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine.Ann Pharmacother. 2006 Apr;40(4):666-73. doi: 10.1345/aph.1G486. Epub 2006 Mar 7. Ann Pharmacother. 2006. PMID: 16595570 Review.
Cited by
-
Importance of circulating antibodies in protection against meningococcal disease.Hum Vaccin Immunother. 2012 Aug;8(8):1029-35. doi: 10.4161/hv.20473. Epub 2012 Aug 1. Hum Vaccin Immunother. 2012. PMID: 22854672 Free PMC article. Review.
-
Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.Eur J Clin Microbiol Infect Dis. 2010 Mar;29(3):259-67. doi: 10.1007/s10096-009-0848-8. Epub 2009 Dec 22. Eur J Clin Microbiol Infect Dis. 2010. PMID: 20033465 Clinical Trial.
-
Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2012 Jan;18(1):145-9. doi: 10.1016/j.bbmt.2011.07.027. Epub 2011 Aug 4. Biol Blood Marrow Transplant. 2012. PMID: 21820392 Free PMC article.
-
Advances in vaccine technology and their impact on managed care.P T. 2008 Jan;33(1):35-41. P T. 2008. PMID: 19749990 Free PMC article.
-
Validation of an FFF-MALS Method to Characterize the Production and Functionalization of Outer-Membrane Vesicles for Conjugate Vaccines.Anal Chem. 2022 Sep 6;94(35):12033-12041. doi: 10.1021/acs.analchem.2c01590. Epub 2022 Aug 25. Anal Chem. 2022. PMID: 36007249 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
